Consider yourself as a gynecological oncologist super speciality resident of NBEMS. Solve this question paper. Give your answer in word file. Use latest medical guidelines and evidences. Don't write long sentances. Give maximum answers in tables, flowchart and diagrams. Each answer should be atleast five A4 size page long.
You are a gynecological oncology NBEMS super-specialty resident. Research ALL 10 questions below thoroughly using the medical library database (query_library_db), PubMed (pubmed_search with date_range_years=3), and web_search. Compile detailed, evidence-based notes for each question. Return structured content (bullet points, table data, flowchart steps) ready to be formatted into a Word document. QUESTIONS: 1. Risk categorization in Ca endometrium per recent guidelines (ESGO/ESMO/ESTRO 2023). Briefly describe PORTEC 4a trial and clinical implications. [6+4] 2. Management of platinum resistant ovarian carcinoma with evidence. [10] 3. Critically evaluate WHO analgesic ladder for cancer pain management. Briefly describe management of malignant bowel obstruction. [5+5] 4. Biological rationale behind concurrent chemotherapy during radiation. Common chemo regimens with RT in carcinoma cervix. Keynote A18 trial. [3+4+3] 5. Homologous recombinant repair deficiency and PARP inhibition leading to cell death. PARPi use in recurrent ovarian carcinoma with evidence. [4+6] 6. WHO criteria for a screening program. Crucial parameters when evaluating screening tests. [5+5] 7. Classify uterine sarcomas. Management of uterine embryonal rhabdomyosarcoma in adolescent girl. [5+5] 8. Recent advances in brachytherapy techniques. Long and short-term complications of radiation and their management. [5+5] 9. Evidence supporting and refuting HIPEC in first-line management of advanced ovarian cancer. Peri-operative complications of HIPEC and management. [5+5] 10. End of life care in cancer patients. Management of advanced/metastatic cervical cancer patient with bony pains. [5+5] For each question, provide: - All key facts, clinical data, trial names and results, drug names/doses - Data suitable for tables (e.g., risk groups, drug comparisons, criteria lists) - Data suitable for flowcharts (management algorithms) - Latest guideline references (ESGO 2023, NCCN 2024-2025, ASCO, WHO) - Recent trial data (PORTEC 4a, KEYNOTE-A18, ARIEL3, STUDY 19, PRIMA, PAOLA-1, etc.) Use these tools: - query_library_db: Search medical textbooks - pubmed_search: Search recent evidence (date_range_years=3) - web_search: Get current guidelines Return ALL compiled research as structured text organized by question number, with clear headings and bullet points.
endometrial cancer risk classification ESGO ESMO ESTRO 2023 guidelines
platinum resistant ovarian cancer treatment bevacizumab
KEYNOTE-A18 pembrolizumab chemoradiotherapy cervical cancer
PARP inhibitor HRD homologous recombination deficiency ovarian cancer
ESGO ESMO ESTRO 2023 endometrial cancer risk groups classification guidelines
PORTEC 4a trial endometrial cancer molecular adjuvant radiotherapy 2023 2024
PORTEC-4a molecular classification endometrial cancer adjuvant radiotherapy
mirvetuximab soravtansine platinum resistant ovarian cancer FORWARD
WHO analgesic ladder cancer pain management evaluation critique
malignant bowel obstruction management octreotide corticosteroids
platinum resistant ovarian cancer NCCN 2024 treatment algorithm mirvetuximab
KEYNOTE-A18 trial results pembrolizumab chemoradiation cervical cancer PFS OS 2024
WHO screening program criteria cancer population
uterine sarcoma rhabdomyosarcoma classification management
HIPEC ovarian cancer first line randomized controlled trial
brachytherapy advances MRI guided adaptive cervical cancer
HIPEC ovarian cancer evidence 2023 2024 Van Driel trial controversy guidelines
HRD BRCA PARP inhibitor mechanism synthetic lethality olaparib niraparib rucaparib ovarian cancer
cancer pain management bone metastasis bisphosphonate radiotherapy palliative
HIPEC ovarian cancer interval cytoreduction OVHIPEC survival
end of life care cancer patients advanced directive palliative
uterine sarcoma WHO classification 2023 ESGO guidelines management
WHO 10 criteria screening program Wilson Jungner cancer 2023
embryonal rhabdomyosarcoma uterus adolescent treatment chemotherapy VAC surgery
radiation complications brachytherapy cervical cancer fistula rectal bleeding management 2023
concurrent chemoradiation cervical cancer mechanism radiosensitization cisplatin weekly
WHO analgesic ladder limitations 2023 step 2 controversy adjuvants neuropathic pain
malignant bowel obstruction management algorithm octreotide dexamethasone hyoscine 2024
ESGO EURACAN 2024 uterine sarcoma classification leiomyosarcoma endometrial stromal
bone metastasis cervical cancer management RANK ligand denosumab radiotherapy palliative 2024
niraparib PRIMA ovarian cancer final overall survival
MIRASOL mirvetuximab soravtansine platinum resistant ovarian cancer phase III
OVHIPEC-2 trial results HIPEC primary cytoreduction ovarian cancer 2024
ESMO ovarian cancer guidelines 2023 2024 recurrent platinum resistant treatment recommendations
Continue
You are a gynecological oncology NBEMS super-specialty resident. Research ALL 10 questions below thoroughly using the medical library database (query_library_db), PubMed (pubmed_search with date_range_years=3), and web_search. Compile detailed, evidence-based notes for each question. Return structured content ready to be formatted into a Word document. QUESTIONS: 1. Risk categorization in Ca endometrium per recent guidelines (ESGO/ESMO/ESTRO 2023). Briefly describe PORTEC 4a trial and clinical implications. [6+4] 2. Management of platinum resistant ovarian carcinoma with evidence. [10] 3. Critically evaluate WHO analgesic ladder for cancer pain management. Briefly describe management of malignant bowel obstruction. [5+5] 4. Biological rationale behind concurrent chemotherapy during radiation. Common chemo regimens with RT in carcinoma cervix. Keynote A18 trial. [3+4+3] 5. Homologous recombinant repair deficiency and PARP inhibition leading to cell death. PARPi use in recurrent ovarian carcinoma with evidence. [4+6] 6. WHO criteria for a screening program. Crucial parameters when evaluating screening tests. [5+5] 7. Classify uterine sarcomas. Management of uterine embryonal rhabdomyosarcoma in adolescent girl. [5+5] 8. Recent advances in brachytherapy techniques. Long and short-term complications of radiation and their management. [5+5] 9. Evidence supporting and refuting HIPEC in first-line management of advanced ovarian cancer. Peri-operative complications of HIPEC and management. [5+5] 10. End of life care in cancer patients. Management of advanced/metastatic cervical cancer patient with bony pains. [5+5] For each question provide: - All key facts, clinical data, trial names and results, drug names/doses - Data suitable for TABLES (e.g., risk groups, drug comparisons, criteria lists) - Steps/logic suitable for FLOWCHARTS (management algorithms) - Latest guideline references (ESGO 2023, NCCN 2025, ASCO, WHO) - Recent trial data: PORTEC-4a, KEYNOTE-A18, ARIEL3, STUDY 19, PRIMA, PAOLA-1, JAVELIN-Ovarian, MIRASOL, etc. Use these tools in parallel where possible: - query_library_db: to search medical textbooks - pubmed_search: for recent evidence (date_range_years=3) - web_search: for current guidelines Return ALL compiled research as structured text organized by question number, with clear headings and bullet points. Be thorough - this will be used to write 5+ page answers per question.
endometrial cancer risk classification ESGO ESMO ESTRO 2023 guidelines
platinum resistant ovarian cancer treatment bevacizumab pegylated liposomal doxorubicin
PARP inhibitor recurrent ovarian cancer BRCA HRD maintenance therapy
KEYNOTE-A18 pembrolizumab chemoradiation cervical cancer
HIPEC ovarian cancer first line randomized trial
ESGO ESMO ESTRO 2023 endometrial cancer risk classification guidelines molecular
PORTEC-4a trial results 2023 2024 endometrial cancer adjuvant therapy
KEYNOTE-A18 trial results pembrolizumab concurrent chemoradiation cervical cancer 2023
platinum resistant ovarian cancer management 2024 NCCN guidelines mirvetuximab
HIPEC ovarian cancer OVHIPEC-2 trial 2023 2024 results
WHO cancer screening criteria Wilson Jungner evaluation
uterine sarcoma classification management embryonal rhabdomyosarcoma
malignant bowel obstruction management cancer octreotide corticosteroids
brachytherapy advances image-guided adaptive IGABT cervical cancer outcomes
end of life care cancer palliative symptom management guidelines
MIRASOL trial mirvetuximab soravtansine platinum resistant ovarian cancer results 2023
HRD PARP inhibitor mechanism synthetic lethality BRCA1 BRCA2 DNA repair ovarian cancer
STUDY 19 SOLO2 ARIEL3 PRIMA PAOLA-1 PARP inhibitor maintenance ovarian cancer trial results summary
WHO analgesic ladder 3-step pain management criticism limitations cancer 2023 2024
uterine sarcoma WHO classification 2020 leiomyosarcoma ESS STUMP management guidelines
concurrent chemoradiotherapy cisplatin cervical cancer radiobiology mechanism
HIPEC ovarian cancer perioperative complications morbidity management
bone metastasis cancer pain bisphosphonate denosumab radiation palliative
radiation therapy complications fistula late effects management gynecological cancer
PORTEC-4a molecular profile risk endometrial cancer adjuvant brachytherapy observation
ESGO uterine sarcoma guidelines 2024 embryonal rhabdomyosarcoma vagina uterus management
OVHIPEC-1 final survival analysis 2023 HIPEC interval cytoreductive surgery ovarian cancer results
image guided adaptive brachytherapy IGABT GEC-ESTRO recommendations 2024 cervical cancer outcomes
malignant bowel obstruction cancer management 2024 guidelines octreotide steroids surgery
end of life care dying cancer patient symptom control ASCO palliative 2023 2024 guidelines
Wilson Jungner WHO screening criteria 1968 10 principles cervical cancer screening sensitivity specificity PPV NPV
JAVELIN Ovarian 100 trial avelumab ovarian cancer maintenance 2023 results
rhabdomyosarcoma vagina uterus adolescent girl management COG protocol vincristine actinomycin cyclophosphamide
mirvetuximab soravtansine MIRASOL phase 3 trial ovarian cancer folate receptor
cervical cancer metastatic bone pain palliative radiation bisphosphonate denosumab treatment
concurrent chemoradiation mechanism radiosensitization cisplatin DNA damage repair cell cycle inhibition
FIGO 2023 endometrial cancer staging classification molecular markers POLEmut MMRd NSMP p53abn
brachytherapy HDR LDR PDR recent advances MRI guided TRUS applicators surface mold
OVHIPEC-1 cytoreductive surgery HIPEC interval ovarian cancer survival
WHO screening program criteria sensitivity specificity predictive value cancer